MSIL, Zydus Hospitals tie up for health centre

Ahmedabad: To provide quality healthcare at affordable prices, Maruti Suzuki India Limited (MSIL) has tied-up with Zydus Hospitals to set up a modern polyclinic (health centre) facility at Becharaji near Mehsana.

“Residents of Becharaji and its neighbouring areas need access to quality healthcare at affordable rates. Maruti Suzuki has taken a first step by setting up a polyclinic to offer primary health and diagnostic services,” said MSIL managing director Kenichi Ayukawa, who, along with Zydus Hospitals’ founder chairman Pankaj Patel, inaugurated the facility on Wednesday.

Equipped with advanced diagnostics equipment, the centre will offer facilities such as x-ray, a TMT machine, ECG, pathology laboratory, ultrasound, ambulance and a pharmacy, among others.

The facility will be managed and operated by Ramanbhai Foundation through Zydus Hospitals, a leading healthcare services provider. The centre will be fully funded by MSIL, through its corporate social responsibility (CSR) arm, Maruti Suzuki Foundation.

“Under this CSR initiative, Maruti Suzuki will invest Rs 3.3 crore to set up and fully equip the facility. As services will be offered at subsidized rates, MSIL will bear the cost of maintaining and operating the facility,” the auto giant said in a statement.

Suzuki Motor Corporation (SMC), the parent company of Maruti Suzuki, operates a car manufacturing plant in Becharaji.

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise